Table of Contents

company-logo

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics Dividend Announcement

• Celldex Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Celldex Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Celldex Therapeutics Dividend History

Celldex Therapeutics Dividend Yield

Celldex Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Celldex Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Celldex Therapeutics Financial Ratios

P/E ratio-11.08
PEG ratio-4.81
P/B ratio2.17
ROE-21.49%
Payout ratio0.00%
Current ratio24.27
Quick ratio24.27
Cash Ratio1.13

Celldex Therapeutics Dividend FAQ

Does Celldex Therapeutics stock pay dividends?
Celldex Therapeutics does not currently pay dividends to its shareholders.
Has Celldex Therapeutics ever paid a dividend?
No, Celldex Therapeutics has no a history of paying dividends to its shareholders. Celldex Therapeutics is not known for its dividend payments.
Why doesn't Celldex Therapeutics pay dividends?
There are several potential reasons why Celldex Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Celldex Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Celldex Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Celldex Therapeutics a dividend aristocrat?
Celldex Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Celldex Therapeutics a dividend king?
Celldex Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Celldex Therapeutics a dividend stock?
No, Celldex Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Celldex Therapeutics stocks?
To buy Celldex Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Celldex Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.